URGN — Urogen Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $1.46bn
- $1.51bn
- $109.79m
Annual cashflow statement for Urogen Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -111 | -110 | -102 | -127 | -153 |
| Depreciation | |||||
| Non-Cash Items | 39.4 | 27.6 | 21.7 | 24.9 | 18.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -14.3 | -6.31 | 3.34 | 4.88 | -27.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -84.9 | -87.6 | -76.4 | -96.8 | -162 |
| Capital Expenditures | -0.752 | -0.254 | -0.194 | -0.295 | -0.289 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 4.82 | 1.31 | -0.759 | -20.3 | 61.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 4.07 | 1.06 | -0.953 | -20.6 | 61.6 |
| Financing Cash Flow Items | 72.3 | -0.16 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 72.3 | 97.1 | 117 | 195 | 39.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -8.5 | 10.6 | 39.6 | 77.2 | -61 |